Iron-Deficiency Anemia (IDA)

Definition and Epidemiology

• Systemic nutritional disorder characterized by depletion of total body iron content.
• Impairs heme synthesis, limits erythropoiesis, and induces tissue hypoxia.
• Most prevalent nutritional deficiency globally, affecting over 2 billion individuals.
• Pediatric incidence demonstrates bimodal distribution.
• First peak: 6 months to 3 years. Attributed to rapid somatic growth outstripping dietary intake.
• Second peak: 11 to 17 years. Attributed to pubertal growth spurt and onset of menstrual blood loss in females.

Etiopathogenesis

Nutritional Deficiency

• Inadequate intake constitutes the most common etiology.
• Breastfeeding beyond 6 months without supplemental dietary or medicinal iron.
• Excessive whole cow milk consumption (>24 oz/day).
• Iron bioavailability in cow milk severely limited (~10%) compared to breast milk (20–80%).
• High calcium concentration in bovine milk competitively inhibits iron absorption.
• Vegan or strict vegetarian diets lacking appropriate fortification.

Increased Physiologic Demand

• Prematurity, low birth weight, multiple gestation. Neonatal iron stores proportional to body weight; rapidly depleted by 3-4 months in premature infants compared to 6 months in term infants.
• Rapid somatic growth phases (infancy, adolescence, pregnancy).
• Chronic hypoxia leading to polycythemia (cyanotic congenital heart disease).

Blood Loss (Overt or Occult)

• Perinatal: Fetomaternal hemorrhage, twin-to-twin transfusion, retroplacental bleeding, iatrogenic phlebotomy losses.
• Gastrointestinal: Hypersensitivity to cow milk protein inducing exudative enteropathy and chronic microhemorrhage.
• Anatomic GI lesions: Peptic ulcer disease, Meckel diverticulum, inflammatory bowel disease, polyposis syndromes, hereditary hemorrhagic telangiectasia.
• Parasitic infestation: Endemic areas. Hookworm (Necator americanus, Ancylostoma duodenale), whipworm (Trichuris trichiura), schistosomiasis.
• Genitourinary/Pulmonary: Menorrhagia, abnormal uterine bleeding, recurrent epistaxis, idiopathic pulmonary hemosiderosis, Goodpasture syndrome, paroxysmal nocturnal hemoglobinuria.

Impaired Absorption and Transport

• Gastrointestinal mucosal disease: Celiac disease, tropical sprue, inflammatory bowel disease.
• Gastric alterations: Helicobacter pylori gastritis, antacid therapy, elevated gastric pH, gastric bypass, intestinal resection.
• Iron-Refractory Iron-Deficiency Anemia (IRIDA): Rare autosomal recessive disorder. Pathogenic variant in TMPRSS6 gene (encodes matriptase-2). Abrogates hepcidin inhibition. Elevated hepcidin perpetually blocks intestinal iron absorption and macrophage iron release.
• Genetic transport defects: Atransferrinemia (mutated TF gene), aceruloplasminemia (mutated CP gene).

Pathophysiology: Sequential Stages of Iron Depletion

Stage 1: Iron Depletion

• Depletion of reticuloendothelial tissue iron stores.
• Serum ferritin concentration drops.
• Hemoglobin, hematocrit, and serum iron levels remain strictly normal.

Stage 2: Iron-Deficient Erythropoiesis

• Macrophage iron stores fully exhausted.
• Serum iron declines. Total iron-binding capacity (TIBC) increases.
• Erythropoiesis limited by lack of bioavailable iron.
• Soluble transferrin receptor (sTfR) levels rise. Reticulocyte hemoglobin content (Ret-He) falls.
• Hematocrit remains normal without overt anemia.

Stage 3: Iron-Deficiency Anemia

• Iron deficiency prolonged. Large proportion of circulating erythrocytes produced under iron-limiting conditions.
• Hemoglobin concentration drops below age-adjusted normal range.
• Erythrocytes exhibit microcytosis and hypochromia.
• Red cell distribution width (RDW) increases. Free erythrocyte protoporphyrin (FEP) elevates markedly.

Clinical Manifestations

Hematologic and Systemic

• Insidious onset. Mild stages frequently asymptomatic.
• Early symptoms: Irritability, anorexia, lethargy, easy fatigability, weakness, tachycardia.
• Severe, persistent deficiency: Congestive heart failure, hepatosplenomegaly, dyspnea, flow murmurs.

Non-Hematologic Tissue Effects

• Gastrointestinal: Pica (compulsive craving for sand, dirt, clay, ice). Rapidly reverses with iron therapy prior to hematologic correction.
• Mucocutaneous: Angular stomatitis, atrophic glossitis (smooth, shiny, painful tongue).
• Esophageal: Dysphagia secondary to esophageal webs (Kelly-Paterson syndrome).
• Neurologic: Restless leg syndrome (discomfort relieved by movement; reflects CNS tissue iron deficiency). Apathy, impaired learning, cognitive deficits.
• Integumentary: Koilonychia (spoon-shaped nails), platynychia, marked pallor of palmar creases and conjunctivae.
• Immunologic: Impaired leukocyte transformation, decreased myeloperoxidase activity, heightened susceptibility to respiratory infections.

Diagnostic Evaluation

Primary Blood Indices

• Hemoglobin/Hematocrit: Reduced below age and sex-matched normative limits.
• Red Cell Indices: Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), and Mean Corpuscular Hemoglobin Concentration (MCHC) significantly reduced.
• Red Cell Distribution Width (RDW): Elevated (>14.5%). Indicates marked anisocytosis. Differentiates from thalassemia trait where RDW remains normal (<13%).
• Reticulocyte Count: Relative percentage may appear elevated, but absolute or corrected reticulocyte index is low or normal (<1.5%), reflecting hypoproliferative marrow response.
• Platelet Count: Variable. Reactive thrombocytosis common due to erythropoietin cross-reactivity. Severe IDA may present with thrombocytopenia.

Peripheral Blood Smear

• Erythrocytes exhibit hypochromia (central pallor exceeding 1/3 of cell diameter) and microcytosis (cells smaller than lymphocyte nucleus).
• Marked anisocytosis and poikilocytosis.
• Presence of teardrop cells, ovalocytes, elliptocytes, and occasional target cells.

Biochemical Iron Profile

• Serum Ferritin: <15 ng/mL. Highly specific and sensitive indicator of depleted body stores. Acute-phase reactant properties may falsely elevate levels during concurrent infection, inflammation, or malignancy.
• Serum Iron: Markedly reduced.
• Total Iron-Binding Capacity (TIBC): Increased.
• Transferrin Saturation: Reduced to <16% (Normal: 25-50%).

Advanced Diagnostic Markers

• Soluble Transferrin Receptor (sTfR): Elevated. Superior marker in complex cases as it remains unaffected by systemic inflammation.
• sTfR/log ferritin ratio: Highest diagnostic sensitivity and specificity. Ratio >2.9 confirms IDA, distinguishing it from anemia of chronic disease.
• Free Erythrocyte Protoporphyrin (FEP): Elevated. Reflects accumulation of protoporphyrin unable to bind absent iron for ultimate heme synthesis.
• Reticulocyte Hemoglobin Content (Ret-He): Reduced. Highly sensitive early indicator of iron-deficient erythropoiesis. First parameter to correct upon treatment initiation.
• Zinc Protoporphyrin/Heme Ratio: Increased. Zinc substitutes for iron within protoporphyrin IX ring during deficiency states.

Differential Diagnosis of Microcytic Anemias

Parameter	Iron-Deficiency Anemia	Beta-Thalassemia Trait	Anemia of Chronic Inflammation	Sideroblastic Anemia
Pathophysiology	Depleted iron stores	Globin chain imbalance	Iron sequestration	Mitochondrial iron utilization defect
Red Cell Count	Reduced	Elevated	Normal to low	Normal to low
RDW	Elevated (13-15%)	Normal	Normal or mildly increased	Elevated
Serum Iron	Low	Normal	Low	Elevated
TIBC	Elevated	Normal	Low or Normal	Normal to low
Serum Ferritin	Low (<15 ng/mL)	Normal to high	Normal to high	Elevated
sTfR	Elevated	Normal or slightly elevated	Normal	Normal
Peripheral Smear	Microcytic, hypochromic, anisocytosis, ovalocytes	Microcytic, hypochromic, target cells, fine basophilic stippling	Normocytic to microcytic	Dimorphic population, basophilic stippling
Bone Marrow	Absent iron stores	Normal or increased iron	Increased macrophage iron, absent sideroblasts	Ringed sideroblasts (>10%)

Note: Diagnosis of beta-thalassemia trait via elevated HbA2 may be masked by concomitant IDA. Definitive hemoglobin electrophoresis should be delayed until iron stores are repleted.

Management Principles

Etiologic Correction and Dietary Counseling

• Address primary underlying etiology universally. Refer for gastroenterology endoscopy if occult bleeding suspected in non-menstruating populations.
• Exclusively breastfed infants: Initiate iron supplementation (1 mg/kg/day) at 4 months of age. Continue until adequate solid food intake.
• Premature infants: Initiate prophylactic iron (2 mg/kg/day) by 2 weeks of age.
• Limit cow milk consumption: Strictly avoid in first year of life. Restrict to <24 oz/day in toddlers to prevent occult enteropathy.
• Promote iron-rich dietary transition: Fortified cereals, meat, fish, and poultry.
• Dietary modifiers: Ascorbic acid (vitamin C) enhances enteral non-heme iron absorption. Discourage concomitant intake of tea, phytates, and phosphates.

Oral Iron Therapy

• First-line definitive management modality.
• Preparation: Ferrous sulfate (20% elemental iron) most economical and efficacious. Ferric compounds demonstrate inferior absorption.
• Dosage: 3 to 6 mg/kg/day of elemental iron.
• Administration: Maximize absorption by administering on empty stomach or between meals. Every-other-day dosing may improve GI tolerance and absorption efficiency in selected patients.
• Duration: Continue therapy for 4 to 6 months following complete hemoglobin normalization to replenish reticuloendothelial iron stores.
• Adverse Effects: Epigastric discomfort, nausea, vomiting, constipation, diarrhea, metallic taste, and harmless dark stools.

Monitoring Therapeutic Response

• Bone marrow megaloblastosis reverses within days, but not applicable for isolated IDA. Reticulocyte crisis observed at 5 to 10 days post-initiation.
• Hemoglobin concentration rises 0.25 to 0.4 g/dL/day initially. Target minimum increase of 1 g/dL at 1 month of therapy.
• Failure to respond mandates reassessment: Evaluate compliance, inadequate dose, persistent occult hemorrhage, concurrent malabsorption (celiac disease), concurrent inflammation, incorrect diagnosis (thalassemia trait), or IRIDA.

Parenteral Iron Therapy

• Indications limited to specific clinical scenarios: Severe GI intolerance, complete non-adherence to oral regimens, malabsorption syndromes (celiac disease, inflammatory bowel disease, prior gastrectomy), ongoing rapid hemorrhage exceeding enteral absorptive capacity, and congenital IRIDA.
• Concomitant use indicated with recombinant erythropoietin therapy (renal dialysis, oncology patients) to guarantee steady substrate supply.
• Formulations: Iron sucrose, ferric carboxymaltose, iron dextran. Intravenous administration mandatory; intramuscular injection strictly contraindicated due to severe pain, tissue staining, and erratic absorption.
• Dosage Calculation (Ganzoni Formula): Total cumulative dose (mg) = [Target Hb - Actual Hb] × Weight (kg) × 2.4 + [15 × Weight (kg)]. Test dose required for specific formulations like high-molecular-weight iron dextran.

Blood Transfusion

• Strictly contraindicated for routine correction of IDA. Reserved exclusively for acute emergencies.
• Indications: Severe, life-threatening anemia (Hb <4 g/dL), overt signs of congestive heart failure, imminent cardiovascular collapse, rapid uncontrolled hemorrhage, or urgent requirement for general anesthesia/surgery.
• Administration: Packed red blood cells. Slow continuous infusion rate (2 to 3 mL/kg) under stringent cardiovascular monitoring to prevent fatal volume overload.
• Partial exchange transfusion may be required to rapidly increase oxygen-carrying capacity without precipitating acute cardiac decompensation. Concomitant diuretic therapy frequently indicated.